Related Experiment Video
Updated: Jul 2, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Challenges for drug studies in children: CYP3A phenotyping as example
Saskia N de Wildt1, Shinya Ito, Gideon Koren
1Division of Clinical Pharmacology and Toxicology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada. s.dewildt@utoronto.ca
Drug Discovery Today
|August 30, 2008
Summary
Limited data exists on pediatric drug disposition. This review addresses challenges and solutions for studying drug absorption, distribution, metabolism, and excretion (ADME) in children, focusing on CYP3A enzyme activity.
Area of Science:
- Pharmacology
- Pediatric Drug Development
- Drug Metabolism
Background:
- Significant data gaps exist regarding drug disposition and effects in young children.
- Understanding pediatric drug pharmacokinetics is crucial for safe and effective treatment.
- Cytochrome P450 3A (CYP3A) is a key enzyme in drug metabolism, affecting over half of all marketed drugs.
Purpose of the Study:
- To identify ethical, practical, and scientific challenges in studying drug disposition in pediatric populations.
- To propose feasible solutions for investigating drug pharmacokinetics, specifically CYP3A phenotyping, in young children.
- To enhance the prediction of drug behavior across the entire pediatric age range.
Main Methods:
- Review of existing methodologies for assessing in vivo drug-metabolizing enzyme activity.
- Identification of challenges specific to pediatric research, including ethical considerations and practical limitations.
- Focus on CYP3A phenotyping as a model for studying drug metabolism in children.
Main Results:
- The review highlights the scarcity of in vivo data on drug ADME in pediatric populations.
- Specific challenges in pediatric drug disposition studies are detailed, including ethical and practical hurdles.
- Potential solutions and approaches for overcoming these challenges are discussed, using CYP3A as an example.
Conclusions:
- Addressing the challenges in pediatric drug disposition studies is essential to fill critical knowledge gaps.
- Elucidating developmental ADME principles can enable better prediction of drug effects in children.
- Further research, with tailored methodologies, is needed to understand drug metabolism, particularly CYP3A activity, in pediatric patients.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...